DOW JONES21,413.44+469.93 2.24%
S&P 5002,526.90+56.40 2.28%
NASDAQ7,487.31+126.73 1.72%

Citigroup Maintains Buy on Fate Therapeutics, Raises Price Target to $41

Citigroup maintains Fate Therapeutics (NASDAQ:FATE) with a Buy and raises the price target from $26 to $41.

Benzinga · 03/04/2020 12:49

Citigroup maintains Fate Therapeutics (NASDAQ:FATE) with a Buy and raises the price target from $26 to $41.